Evidence-Based Recommendations for Therapeutic Options and Newly Approved and Emerging Treatments in Atopic DermatitisPremiere Date: Friday, May 12, 2017
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, May 12, 2018
|Zelma C. Chiesa Fuxench, MD, MSCE, FAAD
Assistant Professor of Dermatology
Department of Dermatology
University of Pennsylvania Perelman School of Medicine
|Mark G. Lebwohl, MD
Sol and Clara Kest Professor and Chair
The Kimberly and Eric J. Waldman Professor
Chairman of The Kimberly and Eric J. Waldman
Department of Dermatology
Icahn School of Medicine
Mount Sinai Medical Center
New York, NY
Atopic dermatitis (AD) or atopic eczema is a chronic inflammatory skin disorder characterized by an itchy, red rash most commonly found in skin creases.1 It is prevalent in 25% of children and 2% to 3% of adults.2 Quality of life issues associated with atopic dermatitis include: severe itching and resulting sleep loss, social stigma, negative impact on interpersonal relationships, loss of wages, loss of work and school productivity, restrictions on some activities, frequent applications of medication, costs of treatment, and frequent visits to health care professionals.1,2 Education to dermatologists is needed to close gaps related to utilizing evidence-based recommendations for therapeutic options and tailoring treatment to individual patients to improve quality of life.
In this CME Outfitters Snack, expert faculty bring the patient voice to life by incorporating patient feedback as they discuss new and emerging treatments for atopic dermatitis.
1. Thomas K, Bath-Hextall F, Ravenscroft J, Charman C, Williams H. Chapter 19: atopic eczema. In: Williams H, ed. Evidence-Based Dermatology. 2nd ed. Hoboken, NJ: Wiley and Sons: 2009: pp. 128-163.
2. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.
At the end of this CE activity, participants should be able to:
- Translate evidence-based recommendations for therapeutic options in treating patients with atopic dermatitis (AD).
- Incorporate mechanism of action and risks and benefits for newly approved or emerging agents (when available) for AD into treatment decisions.
Supported by Sanofi US and Regeneron Pharmaceuticals.
Physicians, pharmacists, and other health care professionals who treat patients with atopic dermatitis.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs) Universal Activity Number:
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chiesa Fuxench reports that she receives grants from Dermatology Foundation; and Women's Dermatological Society. She receives research support from Regeneron Pharmaceuticals; Tioga Pharmaceuticals; and Vanda Pharmaceuticals. She is a consultant for Asthma and Allergy Foundation of America; and National Eczema Association.
Dr. Lebwohl reports that he is an employee of the Mount Sinai Medical Center which receives research funds from AbbVie Inc.; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Boehringer Ingleheim; Celgene Corporation; Eli Lilly and Company; Janssen Research & Development, LLC; Kadmon Holdings, Inc.; Medimmune/Astra Zeneca; Novartis; Pfizer Inc.; and Vidac.
Erica Perilstein, MD (peer reviewer) has nothing to disclose.
Daniela V. DiBiase, MS (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).